Insider Buying: Generation Bio Co. (NASDAQ:GBIO) Director Acquires 125,791 Shares of Stock

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn bought 125,791 shares of the stock in a transaction on Friday, January 10th. The stock was purchased at an average cost of $0.96 per share, with a total value of $120,759.36. Following the acquisition, the director now owns 214,286 shares in the company, valued at approximately $205,714.56. This represents a 142.14 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Generation Bio Stock Down 4.3 %

GBIO traded down $0.04 during trading on Tuesday, hitting $0.88. The company’s stock had a trading volume of 932,699 shares, compared to its average volume of 609,204. The firm has a market capitalization of $58.78 million, a P/E ratio of -0.40 and a beta of 2.72. Generation Bio Co. has a twelve month low of $0.75 and a twelve month high of $4.65. The stock’s fifty day moving average price is $1.35 and its 200-day moving average price is $2.13.

Institutional Investors Weigh In On Generation Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its stake in shares of Generation Bio by 165.5% during the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock worth $189,000 after purchasing an additional 47,639 shares during the last quarter. State Street Corp raised its stake in Generation Bio by 1.2% in the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock valued at $2,451,000 after acquiring an additional 11,669 shares during the period. Baker BROS. Advisors LP lifted its stake in shares of Generation Bio by 61.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after buying an additional 737,988 shares in the last quarter. FMR LLC boosted its holdings in shares of Generation Bio by 0.3% in the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock worth $13,141,000 after acquiring an additional 15,656 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Generation Bio by 2.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock valued at $1,046,000 after purchasing an additional 8,692 shares in the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GBIO shares. Wedbush reiterated an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a research report on Thursday, November 7th. Needham & Company LLC reduced their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.